Edwards Lifesciences Corporation
EW
$81.83
$0.670.83%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.69B | 5.52B | 5.44B | 5.32B | 5.21B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.69B | 5.52B | 5.44B | 5.32B | 5.21B |
| Cost of Revenue | 1.20B | 1.13B | 1.12B | 1.08B | 1.06B |
| Gross Profit | 4.48B | 4.39B | 4.32B | 4.24B | 4.15B |
| SG&A Expenses | 1.88B | 1.83B | 1.79B | 1.71B | 1.67B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.70M | -19.40M | -300.00K | -153.60M | -176.00M |
| Total Operating Expenses | 4.10B | 3.99B | 3.96B | 3.66B | 3.57B |
| Operating Income | 1.59B | 1.53B | 1.48B | 1.66B | 1.63B |
| Income Before Tax | 1.63B | 1.61B | 1.55B | 1.53B | 1.51B |
| Income Tax Expenses | 220.40M | 176.10M | 152.10M | 141.10M | 153.10M |
| Earnings from Continuing Operations | 1.41K | 1.43K | 1.40K | 1.38K | 1.36K |
| Earnings from Discontinued Operations | 2.74B | 2.74B | 2.77B | 2.77B | 112.50M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.00M | 5.60M | 4.90M | 3.80M | 3.60M |
| Net Income | 4.15B | 4.18B | 4.17B | 4.16B | 1.47B |
| EBIT | 1.59B | 1.53B | 1.48B | 1.66B | 1.63B |
| EBITDA | 1.74B | 1.69B | 1.64B | 1.81B | 1.79B |
| EPS Basic | 6.97 | 7.01 | 6.99 | 6.95 | 2.44 |
| Normalized Basic EPS | 1.81 | 1.74 | 1.68 | 1.84 | 1.78 |
| EPS Diluted | 6.97 | 7.01 | 6.99 | 6.94 | 2.43 |
| Normalized Diluted EPS | 1.81 | 1.74 | 1.67 | 1.84 | 1.77 |
| Average Basic Shares Outstanding | 2.36B | 2.38B | 2.39B | 2.41B | 2.42B |
| Average Diluted Shares Outstanding | 2.36B | 2.38B | 2.40B | 2.41B | 2.42B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |